← All trials
NCT03043560
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2017
- Primary completion
- Apr 15, 2019
- Completion date
- May 15, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- National Institute of Mental Health (NIMH)Collaborator
- Baylor UniversityCollaborator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.